IL11 and nonpapillary renal cell carcinoma: Considering the important role of IL-11/STAT3 signaling pathway in tumor progression and metastasis, therapeutic options using direct STAT3 inhibitors or upstream inhibitors might be used for the treatment of ccRCC in the future.